AI ECG Cardiac Screening Patents

AI ECG cardiac screening patents cover AI-algorithm innovations; hidden-disease-detection innovations; single-lead/wearable innovations; and ambulatory, validation, and workflow innovations — with IP held by cardiac-AI companies and device makers (in a field using AI to analyze ECGs to detect arrhythmias and even diseases invisible to human readers). WHY AI ECG: the ECG is cheap, ubiquitous, and information-rich; AI can detect ARRHYTHMIAS (atrial fibrillation) at scale (consumer wearables) AND — remarkably — extract signals of HIDDEN cardiac disease that cardiologists CAN'T see in a normal-looking ECG (low ejection fraction/heart failure, hyperkalemia, valvular disease, future AFib risk), enabling cheap, scalable screening for serious conditions. MAJOR AI-ECG PATENT HOLDERS: ALIVECOR (KardiaMobile personal single-lead ECG + AI), EKO HEALTH (AI digital stethoscope — ECG + heart sounds), ANUMANA (Mayo Clinic + nference — AI-ECG algorithms detecting HIDDEN disease, e.g., low EF/hyperkalemia), CARDIOLOGS (Philips — AI arrhythmia analysis), APPLE (Watch ECG/AFib), iRHYTHM (Zio patch + AI long-term monitoring), GE/Philips ECG. AI algorithms, hidden-disease detection, single-lead/wearable, and ambulatory/validation/workflow are the core AI-ECG patent domains — and hidden-disease detection, wearable/single-lead AI, and validated screening are the open whitespace.

AI-ECG-algorithm innovations; arrhythmia-detection innovations; HIDDEN-disease-detection innovations; and §101 and validation considerations represent core AI-ECG patent domains — and the AI that finds disease (especially INVISIBLE disease) in ECG signals is the central value, while §101 shapes how to claim it. AI-ECG-ALGORITHM PATENTS: deep-learning models analyzing the ECG WAVEFORM — feature extraction, model architectures for time-series ECG, and turning raw ECG into clinical predictions; the algorithm is core (but software/AI faces §101 abstract-idea scrutiny — claim specific technical methods/systems, not 'use AI on an ECG'). ARRHYTHMIA-DETECTION PATENTS: detecting/classifying arrhythmias — atrial FIBRILLATION (the big one, esp from consumer single-lead), and other rhythm disorders; automated arrhythmia detection (and reducing false positives) is high-value. HIDDEN-DISEASE-DETECTION PATENTS: the remarkable differentiator — AI extracting signals of disease that humans CANNOT see in a normal-appearing ECG — LOW EJECTION FRACTION/heart failure, HYPERKALEMIA (high potassium), valvular disease, hypertrophic cardiomyopathy, and even biological age/sex (Anumana/Mayo); these 'AI-ECG' hidden-disease detectors are the highest-value, most novel IP (a new diagnostic capability, not just automating a cardiologist). §101 / VALIDATION CONSIDERATIONS: AI-diagnosis methods face ABSTRACT-IDEA eligibility (Alice/Mayo — and ironically a famous diagnostic case IS Mayo) — claim concrete technical systems; and clinical VALIDATION (sensitivity/specificity, prospective trials) is essential for credibility/FDA. Hidden-disease detection (invisible-to-human signals), robust arrhythmia detection, and §101-defensible technical claims are the highest-value algorithm IP because detecting disease humans can't see (validated) is a genuinely new, defensible diagnostic capability.

Single-lead/wearable innovations; digital-stethoscope/multimodal innovations; ambulatory/patch innovations; and FDA, false-positive, and workflow innovations represent additional AI-ECG patent domains — and acquiring good ECG from consumer/wearable devices, combining signals, and integrating into care are where deployment value sits. SINGLE-LEAD / WEARABLE PATENTS: getting diagnostic-quality ECG from CONSUMER devices — single-lead (smartwatch/handheld — Apple Watch, KardiaMobile) AFib detection, signal acquisition from non-clinical electrodes, motion/noise handling, and on-device AI; single-lead/wearable AI (vs 12-lead clinical) is high-value (mass screening). DIGITAL-STETHOSCOPE / MULTIMODAL PATENTS: combining ECG with other signals — heart SOUNDS (phonocardiogram — Eko digital stethoscope detects murmurs/valve disease + ECG), and multimodal AI; multimodal cardiac screening is differentiating. AMBULATORY / PATCH PATENTS: long-term monitoring — wearable PATCHES (iRhythm Zio — days-weeks of continuous ECG) + AI to find intermittent arrhythmias, and ambulatory analysis; patch + AI is high-value for catching paroxysmal events. FDA / FALSE-POSITIVE / WORKFLOW PATENTS: FDA SaMD clearance (consumer + clinical), minimizing FALSE POSITIVES (critical for screening — false AFib alerts cause harm/cost), EHR integration, and clinical workflow/notification; false-positive reduction and validated, integrated screening are essential. Single-lead/wearable AI, multimodal (ECG + sound) screening, patch+AI ambulatory monitoring, and false-positive-reduced FDA-cleared workflows are the highest-value application IP because consumer-quality acquisition, multimodal signals, long-term monitoring, and clinically-trustworthy screening determine real-world impact.

AI ECG startup IP strategy must navigate AliveCor/Eko/Anumana/Cardiologs/iRhythm and Apple/GE/Philips portfolios, the §101 abstract-idea problem (AI diagnosis), the proprietary-DATA moat (large labeled ECG datasets — often trade-secret), the FDA SaMD and clinical-validation realities (and FALSE-POSITIVE risk in screening), the consumer-vs-clinical and arrhythmia-vs-hidden-disease strategy, and a landscape where AI algorithms (esp hidden-disease), wearable/single-lead, and validated workflows are the durable assets; understand that arrhythmia detection is increasingly competitive, so the durable IP is in HIDDEN-disease detection, multimodal/wearable acquisition, false-positive reduction, and validated screening — with proprietary ECG data often the real moat, and that §101-defensibility, data, validation, and false-positive performance matter as much as patents; identify whitespace in hidden-disease detection, wearable AI, and multimodal screening. AI-ECG STARTUP IP STRATEGY: ARRHYTHMIA DETECTION IS CROWDED — HIDDEN-DISEASE DETECTION, WEARABLE/MULTIMODAL ACQUISITION, AND VALIDATED SCREENING ARE THE IP: AFib detection is competitive, so patent hidden-disease detection, wearable/multimodal acquisition, false-positive reduction, and validated screening — not generic 'AI ECG arrhythmia'; HIDDEN-DISEASE DETECTION IS THE HIGHEST-VALUE, MOST NOVEL WHITESPACE: AI finding disease HUMANS CAN'T SEE in a normal ECG (low EF/hyperkalemia/valve disease — Anumana/Mayo) is a genuinely new diagnostic capability and the most defensible, valuable IP; §101 LIMITS PATENTING AI METHODS — CLAIM CONCRETE TECHNICAL SYSTEMS: AI diagnosis faces abstract-idea rejection (the Mayo case is itself a diagnostic-eligibility landmark) — claim specific technical methods/systems/acquisition, not abstract 'AI predicts disease'; PROPRIETARY ECG DATA IS OFTEN THE REAL MOAT (TRADE-SECRET): large, labeled, outcome-linked ECG datasets and trained models drive accuracy — weigh trade secret vs patent (Mayo/Anumana's data is a key asset); FALSE-POSITIVE REDUCTION IS CRITICAL FOR SCREENING: at population scale, false positives cause harm/cost/distrust — minimizing them (and proving specificity) is high-value; SINGLE-LEAD/WEARABLE ACQUISITION ENABLES MASS SCREENING: diagnostic-quality AI from consumer single-lead/wearables (Apple/Kardia) is a key, defensible capability; MULTIMODAL (ECG + HEART SOUNDS) DIFFERENTIATES: combining signals (Eko) catches more (valve disease via murmurs); FDA CLEARANCE AND CLINICAL VALIDATION GATE THE BUSINESS: SaMD clearance and prospective validation matter as much as patents; WHEN TO PATENT (OR KEEP SECRET): NOVEL ALGORITHM/ACQUISITION/SCREENING WITH MEASURED PERFORMANCE AND §101 IN MIND: file (or trade-secret data/models) once a method shows measured results (detection sensitivity/specificity/AUC + hidden-disease accuracy + false-positive rate + wearable/single-lead performance + validation + clinical outcome) AND can be claimed concretely — measured hidden-disease accuracy, false-positive rate, and validation are the critical AI-ECG IP metrics; KEY FTO CHECKLIST: AliveCor KardiaMobile single-lead AI; Eko digital stethoscope ECG+sound; Anumana/Mayo hidden-disease AI-ECG (low EF/hyperkalemia); Cardiologs/Philips arrhythmia; Apple Watch ECG/AFib; iRhythm Zio patch+AI; AI ECG waveform deep-learning algorithm (§101); arrhythmia/AFib detection; HIDDEN-disease detection (low EF/hyperkalemia/valve/HCM/age-sex); single-lead/wearable acquisition/noise; digital-stethoscope/multimodal ECG+phonocardiogram; ambulatory patch + AI; false-positive reduction/specificity; FDA SaMD (consumer/clinical); proprietary ECG data/model trade-secret; EHR/workflow; §101 Mayo/Alice.